Clinical trials: Regorafenib
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment
There is no definitive evidence regarding the therapeutic efficacy of PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) after disease progression following first-line treatment with bevacizumab plus sintilimab for…
- Trial name
- NCT07537985
- Testing
- Lenvatinib, Regorafenib, PD-1 Inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Colorectal Adenocarcinoma
Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer
- Trial name
- REGOLD (NCT02788006)
- Testing
- Regorafenib 160 mg
- Where
- 16 sites in France
- Volunteers
- 43 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
MSS, pMMR
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.
- Conditions
- MSS, pMMR, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT04483219
- Testing
- TKI ± anti-PD-1 antibody
- Where
- China
- Volunteers
- 53 people
- Sponsor
- China Medical University, China
Colorectal Cancer
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
The study is an interventional Phase II clinical trial aiming to optimize immunotherapy strategies for microsatellite-stable colorectal cancer.
- Trial name
- NCT05985109
- Testing
- KN046, regorafenib
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
- Trial name
- NCT05024539
- Testing
- nonintervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shujun Yang
Advanced Gastrointestinal Cancer
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or…
- Trial name
- NCT02024607
- Testing
- BBI608, Fluorouracil, Oxaliplatin
- Where
- 15 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pharmacokinetics
Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
The purpose of this study is to estimate the effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of BAY73-4506 in healthy male volunteers.
- Trial name
- NCT01318265
- Testing
- Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Small Cell Lung Carcinoma
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
This is a multi-center, open-label, non-randomized Phase I study to define the safety profile, maximum tolerated dose (MTD) and potential pharmacokinetic interaction of regorafenib in combination with pemetrexed and cisplatin in…
- Trial name
- NCT01187615
- Testing
- Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bayer
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Hepatocellular Carcinoma
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.
- Trial name
- NCT05155189
- Testing
- C-CAR031, Lenvatinib, Regorafenib (BAY 73-4506)
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Oncology
Regorafenib Phase I Study in Mainland Chinese Patients
The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors.
- Trial name
- NCT02398513
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Bayer
Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy .
- Trial name
- NCT05644379
- Testing
- Cadonilimab Injection, Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-resectable
Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line treatment for patients with unresectable hepatocellullar carcinoma (HCC).
- Trial name
- REGSIN (NCT04718909)
- Testing
- Regorafenib + sintilimab, Regorafenib
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Colorectal Cancer
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
This study is designed to evaluate the safety, tolerability, and efficacy of Epalolitovoreli Monoclonal Antibody (QL1706) combined with Fruquintinib and Short-Course Radiotherapy (SCRT), compared with standard third-line therapy…
- Trial name
- NCT07353268
- Testing
- QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART), Standard Third-Line Therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Tao Zhang
GIST, Malignant, KIT Exon 13 Mutation
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST
This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and/or unresectable GIST after prior failure or intolerability of imatinib.
- Conditions
- GIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation
- Trial name
- POETIG (NCT03171389)
- Testing
- Ponatinib 30 MG
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Sebastian Bauer
Metastatic Colorectal Cancer
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine …
- Trial name
- NCT03564938
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 13 sites in India
- Volunteers
- 100 people
- Sponsor
- Bayer
ALK Fusion Protein Expression, BRAF wt Allele
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma.
- Conditions
- ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive
- Trial name
- NCT02587650
- Testing
- Capmatinib, Ceritinib, Entrectinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Melanoma Stage III, Melanoma Stage IV
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
There are in total 3 cohorts. Cohort A: 16 patients will receive a daily dose of 80mg regorafenib up until progressive disease, unacceptable toxicity or withdrawal of consent.
- Trial name
- RegoMel (NCT05370807)
- Testing
- Regorafenib 40 MG Oral Tablet, Triplet therapy
- Where
- Belgium
- Volunteers
- 48 people
- Sponsor
- Universitair Ziekenhuis Brussel